Amgen’s leukemia drug gets conditional European approval Acute Lymphoblastic Leukemia (ALL), Biotech, Bispecific Antibody, EU, Health, Leukemia, M&A, Pricing, Stocks European health regulators on Friday conditionally approved Amgen Inc’s rare blood cancer drug, Blincyto, which is one of the world’s most expensive cancer treatments. The U.S. Food and Drug Administration […] Read more September 25, 2015/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2015-09-25 09:43:472015-09-25 12:10:44Amgen's leukemia drug gets conditional European approval
